𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I/II study of S-1 combined with carboplatin in recurrent and/or metastatic head and neck cancer as outpatient chemotherapy

✍ Scribed by Akihito Watanabe; Masanobu Taniguchi; Tetsuro Yamashita; Michihiro Ueda; Tatsuya Abe; Takaya Kusumi; Masao Hosokawa; Shigeyuki Sasaki

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
115 KB
Volume
28
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background.

The aims of this study were to determine the recommended dose (RD) in combination chemotherapy of S‐1 and carboplatin in recurrent and/or metastatic head and neck cancer (phase I) and to examine response rate and toxicities at RD (phase II).

Methods.

S‐1 was given orally at a fixed dose of 40, 50, or 60 mg twice daily based on the patient's body surface area for 21 days followed by a 14‐day rest. In phase I, carboplatin was given intravenously to a cohort of three patients on day 8 at a dose of 2.5, 3.0, 3.5, or 4.0 area under the curve (AUC) values, depending on the dose‐limiting toxicities (DLTs).

Results.

In phase I, the RD was estimated as 2.5 AUC. In phase II, thrombocytopenia and leukopenia were most commonly found as hematologic DLTs, which were manageable without hospitalization. The response rate was 40.9%.

Conclusions.

This regimen is considered to be active against recurrent and/or metastatic head and neck cancer in an outpatient setting. Β© 2006 Wiley Periodicals, Inc. Head Neck, 2006

πŸ“œ SIMILAR VOLUMES

A phase II study of piritrexim in combin
A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer
✍ Everett E. Vokes; Isaiah W. Dimery; Charlotte D. Jacobs; Daniel Karp; Arturo Mol πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 468 KB πŸ‘ 2 views

Thirty patients with recurrent and/or metastatic head and neck cancer were treated with sequentially administered methotrexate (MTX) and piritrexim (PTX). The treatment schedule consisted of intravenous (IV) MTX (50 mg/m') administered on day 1 and oral PTX (75 mg/mz) administered twice daily on day

Toxicity and outcome analysis of patient
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies
✍ Noel M. Kramer; Eric M. Horwitz; Jonathan Cheng; John A. Ridge; Steven J. Feigen πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 205 KB πŸ‘ 1 views

## Abstract ## Background. Patients with local recurrences or new head and neck primary tumors in previously irradiated tissues have few options for salvage treatment. One option for select patients is to undergo reirradiation with concurrent chemotherapy. The purpose of this study is to report th